Compare Gilead Sciences, Inc. (GILD) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Target Corporation — how do they compare? Gilead Sciences, Inc. trades at $135.77 (market cap $168.35B), while Target Corporation trades at $153.54 (market cap $69.17B). The key difference: Gilead Sciences, Inc. is far larger — about 2.4× Target Corporation's market cap, and Target Corporation pays the higher dividend (3.05%). Which is the better fit depends on your goals.
| GILD | TGT | |
|---|---|---|
Market Cap | $168.35B | $69.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $152.35 |
52-Week Low | $110.56 | $83.68 |
Enterprise Value | $191.42B | $84.47B |
Dividend Yield | 2.42% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
Target Corporation (TGT) trades at $152.85, up 0.5% today, near its 52-week high. The stock shows strong momentum with bullish technical signals and consistent earnings beats in recent quarters. Revenue remains stable around $106 billion, with a net income margin of 3.24% and solid cash flow from operations of $7.37 billion in 2025. Recent news includes the appointment of a chief AI officer, highlighting strategic focus on technology.
The outlook is positive with analyst consensus leaning buy, though valuation multiples like P/E of 20.12 suggest fair pricing. Risks include competitive retail pressures and macroeconomic sensitivity. Upside potential exists if AI initiatives drive efficiency, but investors should monitor Q2 2026 earnings for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
